Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

Granulocytic myeloid-derived suppressor cells (G-MDSCs) promote tumor growth and immunosuppression in multiple myeloma (MM). However, their phenotype is not well established for accurate monitoring or clinical translation. We aimed to provide the phenotypic profile of G-MDSCs based on their prognost...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2020-07, Vol.136 (2), p.199-209
Hauptverfasser: Perez, Cristina, Botta, Cirino, Zabaleta, Aintzane, Puig, Noemi, Cedena, Maria-Teresa, Goicoechea, Ibai, Alameda, Daniel, San José-Eneriz, Edurne, Merino, Juana, Rodríguez-Otero, Paula, Maia, Catarina, Alignani, Diego, Maiso, Patricia, Manrique, Irene, Lara-Astiaso, David, Vilas-Zornoza, Amaia, Sarvide, Sarai, Riillo, Caterina, Rossi, Marco, Rosiñol, Laura, Oriol, Albert, Blanchard, María-Jesús, Rios, Rafael, Sureda, Anna, Martin, Jesus, Martinez, Rafael, Bargay, Joan, de la Rubia, Javier, Hernandez, Miguel-Teodoro, Martinez-Lopez, Joaquin, Orfao, Alberto, Agirre, Xabier, Prosper, Felipe, Mateos, Maria-Victoria, Lahuerta, Juan-José, Blade, Joan, San-Miguel, Jesús F., Paiva, Bruno
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Granulocytic myeloid-derived suppressor cells (G-MDSCs) promote tumor growth and immunosuppression in multiple myeloma (MM). However, their phenotype is not well established for accurate monitoring or clinical translation. We aimed to provide the phenotypic profile of G-MDSCs based on their prognostic significance in MM, immunosuppressive potential, and molecular program. The preestablished phenotype of G-MDSCs was evaluated in bone marrow samples from controls and MM patients using multidimensional flow cytometry; surprisingly, we found that CD11b+CD14−CD15+CD33+HLADR− cells overlapped with common eosinophils and neutrophils, which were not expanded in MM patients. Therefore, we relied on automated clustering to unbiasedly identify all granulocytic subsets in the tumor microenvironment: basophils, eosinophils, and immature, intermediate, and mature neutrophils. In a series of 267 newly diagnosed MM patients (GEM2012MENOS65 trial), only the frequency of mature neutrophils at diagnosis was significantly associated with patient outcome, and a high mature neutrophil/T-cell ratio resulted in inferior progression-free survival (P < .001). Upon fluorescence-activated cell sorting of each neutrophil subset, T-cell proliferation decreased in the presence of mature neutrophils (0.5-fold; P = .016), and the cytotoxic potential of T cells engaged by a BCMA×CD3-bispecific antibody increased notably with the depletion of mature neutrophils (fourfold; P = .0007). Most interestingly, RNA sequencing of the 3 subsets revealed that G-MDSC–related genes were specifically upregulated in mature neutrophils from MM patients vs controls because of differential chromatin accessibility. Taken together, our results establish a correlation between the clinical significance, immunosuppressive potential, and transcriptional network of well-defined neutrophil subsets, providing for the first time a set of optimal markers (CD11b/CD13/CD16) for accurate monitoring of G-MDSCs in MM. •There is a progressive gradient of immunosuppression from immature to mature neutrophils present in the myeloma microenvironment.•CD11b+CD13+CD16+ mature neutrophils are epigenetically deregulated, and their abundance in the myeloma microenvironment is prognostic. [Display omitted]
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.2019004537